International marketsAurora just posted its Q3, which might suggest a good quarter for LABS. Here is a snippet from their international medical sales:
Medical Cannabis:
Medical cannabis net revenue1 was $61.3 million, a 41% increase from the prior year quarter, delivering 76% of Aurora's Q2 2025 consolidated net revenue1 and 98% of adjusted gross profit before fair value adjustments1.
The increase in net revenue1 of $17.8 million was primarily due to higher sales to Australia, Germany, Poland, and the UK, and stabilized sales in Canada.
Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue reached 68% for the three months ended September 30, 2024, compared to 63% in the prior year quarter. The adjusted gross margins before fair value adjustments improved through sustainable cost reductions, higher selling prices in Australia, and improved efficiency in production operations, including sourcing for Europe from Canada.